Gilead Sciences stock hits new highs with strong performance and revenue growth

From Nasdaq: 2025-03-08 03:53:00

Gilead Sciences stock hits new highs as healthcare sector rises amidst market volatility. Trading at $117, GILD has surged nearly 30% YTD. With a $28.75 billion revenue in 2024, Gilead is projected to rebound with a 4% increase in fiscal 2026 to $29.7 billion.

Gilead’s EPS expected to soar 70% in FY25 to $7.87 per share. Trading at a reasonable P/E of 14.6X forward earnings, GILD offers a 2.65% annual dividend yield, surpassing industry averages. Despite recent rally, Gilead remains a Zacks Rank #2 (Buy) stock with upside potential.

A new top semiconductor stock emerges with strong earnings growth and a growing customer base. Positioned to capitalize on AI, ML, and IoT demands, global semiconductor market projected to grow from $452 billion in 2021 to $803 billion by 2028. Opportunity to invest in upcoming semiconductor boom.



Read more at Nasdaq: Buy Gilead Sciences (GILD) Stock at 52-Week Highs?